HBS-101 is a selectively, orally active, brain-penetrant, Midkine (MDK) inhibitor (KD = 38.4 nM). HBS-101 significantly reduces cell viability, clonogenic survival, and invasiveness and increases apoptosis. HBS-101 involves suppression of the Akt/mTOR, STAT3, and NF-kappaB pathways. HBS-101 can be used for the study of Triple-negative breast cancer (TNBC)[1].
Molekulargewicht:
346.41
Reinheit:
99.59
Formel:
C21H24F2O2
Target-Kategorie:
Akt,Apoptosis,mTOR,NF-kappaB,STAT
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
